

ValÃ©rie Vilgrain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4104398/publications.pdf>

Version: 2024-02-01

154
papers

11,625
citations

101384

36
h-index

30848

102
g-index

158
all docs

158
docs citations

158
times ranked

11512
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI is useful to suggest and exclude malignancy in mucinous cystic neoplasms of the pancreas. <i>European Radiology</i> , 2022, 32, 1297-1307.	2.3	4
2	Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes. <i>European Radiology</i> , 2022, 32, 2813-2823.	2.3	6
3	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. <i>Journal of Hepatology</i> , 2022, 76, 343-352.	1.8	30
4	MR imaging features and long-term evolution of benign focal liver lesions in Budd-Chiari syndrome and Fontan-associated liver disease. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 111-120.	1.8	6
5	Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. <i>Journal of Hepatology</i> , 2022, 76, 420-434.	1.8	41
6	Segmental Arterial Mediolysis. <i>Radiology</i> , 2022, 302, 515-515.	3.6	1
7	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2022, 109, 455-463.	0.1	7
8	Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. <i>Hepatology International</i> , 2022, 16, 509-522.	1.9	16
9	Transarterial Radioembolization Versus Atezolizumab+Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. <i>Advances in Therapy</i> , 2022, , 1.	1.3	6
10	Endovascular revascularization of acute arterial mesenteric ischemia: report of a 3-year experience from an intestinal stroke center unit. <i>European Radiology</i> , 2022, 32, 5606-5615.	2.3	12
11	Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. <i>Hepatology</i> , 2022, 76, 1318-1328.	3.6	10
12	Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI. <i>Insights Into Imaging</i> , 2022, 13, 81.	1.6	5
13	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Cancers</i> , 2022, 14, 2634.	1.7	0
14	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
15	Laparoscopic-assisted liver transplantation: A realistic perspective. <i>American Journal of Transplantation</i> , 2022, 22, 3069-3077.	2.6	3
16	Monocrotaline Toxicity Alters the Function of Hepatocyte Membrane Transporters in Rats. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7928.	1.8	2
17	The diagnostic performance of a simulated "short" gadoxetic acid-enhanced MRI protocol is similar to that of a conventional protocol for the detection of colorectal liver metastases. <i>European Radiology</i> , 2021, 31, 2451-2460.	2.3	10
18	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 405-416.	0.7	10

#	ARTICLE	IF	CITATIONS
19	Imaging of disseminated actinomycosis. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 399-401.	1.8	0
20	Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. <i>JHEP Reports</i> , 2021, 3, 100199.	2.6	55
21	Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 3267-3275.	2.3	9
22	Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France. <i>Radiology</i> , 2021, 298, E81-E87.	3.6	57
23	Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 36-49.	0.9	15
24	Quantification of Pancreas Surface Lobularity on CT: A Feasibility Study in the Normal Pancreas. <i>Korean Journal of Radiology</i> , 2021, 22, 1300.	1.5	5
25	Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1343-1350.	2.2	5
26	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , 2021, 43, 1201-1212.	1.1	4
27	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101731.	0.7	2
28	Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 735-742.	1.8	13
29	Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas. <i>JHEP Reports</i> , 2021, 3, 100326.	2.6	7
30	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). <i>European Journal of Cancer</i> , 2021, 154, 46-56.	1.3	10
31	The SVD beamformer with diverging waves: a proof-of-concept for fast aberration correction. <i>Physics in Medicine and Biology</i> , 2021, 66, 18LT01.	1.6	5
32	Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. <i>JHEP Reports</i> , 2021, 3, 100380.	2.6	29
33	Gallbladder Volvulus. <i>Radiology</i> , 2021, 301, 43-43.	3.6	3
34	Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. <i>Radiographics</i> , 2021, 41, 1611-1631.	1.4	32
35	Steatosis Alters the Activity of Hepatocyte Membrane Transporters in Obese Rats. <i>Cells</i> , 2021, 10, 2733.	1.8	2
36	Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 305-313.	1.4	16

#	ARTICLE	IF	CITATIONS
37	Clinical impact of a new cone beam CT angiography respiratory motion artifact reduction algorithm during hepatic intra-arterial interventions. <i>European Radiology</i> , 2020, 30, 163-174.	2.3	11
38	Gender gap in articles published in <i>European Radiology</i> and <i>CardioVascular and Interventional Radiology</i> : evolution between 2002 and 2016. <i>European Radiology</i> , 2020, 30, 1011-1019.	2.3	25
39	Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome. <i>Hpb</i> , 2020, 22, 622-629.	0.1	19
40	Women in radiology: gender diversity is not a metric—it is a tool for excellence. <i>European Radiology</i> , 2020, 30, 1644-1652.	2.3	56
41	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. <i>European Radiology</i> , 2020, 30, 2293-2301.	2.3	65
42	Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT. <i>Abdominal Radiology</i> , 2020, 45, 365-372.	1.0	16
43	CT and MR perfusion techniques to assess diffuse liver disease. <i>Abdominal Radiology</i> , 2020, 45, 3496-3506.	1.0	13
44	Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome. <i>Infectious Diseases</i> , 2020, 52, 838-840.	1.4	6
45	Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2020, 2, 100147.	2.6	15
46	A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. <i>Annals of Medicine</i> , 2020, 52, 367-375.	1.5	28
47	CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. <i>Cancers</i> , 2020, 12, 3089.	1.7	32
48	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with ⁹⁰ Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1736-1742.	2.8	27
49	Contrast-Enhanced CT for the Diagnosis of Acute Mesenteric Ischemia. <i>American Journal of Roentgenology</i> , 2020, 215, 29-38.	1.0	30
50	Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. <i>JHEP Reports</i> , 2020, 2, 100097.	2.6	11
51	New insights in the management of Hepatocellular Adenoma. <i>Liver International</i> , 2020, 40, 1529-1537.	1.9	18
52	Evaluation of liver tumour response by imaging. <i>JHEP Reports</i> , 2020, 2, 100100.	2.6	33
53	Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1608-1618.	0.9	8
54	Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. <i>Radiology</i> , 2020, 295, 361-372.	3.6	17

#	ARTICLE	IF	CITATIONS
55	Relationship of Tumor Radiation- ⁹⁰ Y absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with ⁹⁰ Y in the SARAH Study. <i>Radiology</i> , 2020, 296, 673-684.	3.6	117
56	Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. <i>Hepatology International</i> , 2020, 14, 437-453.	1.9	68
57	Imaging of liver tumours: What's new?. <i>Liver International</i> , 2020, 40, 154-159.	1.9	1
58	Hereditary hemorrhagic telangiectasia and liver involvement. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 426-432.	0.7	5
59	Budd-Chiari syndrome. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 420-425.	0.7	9
60	CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria. <i>Abdominal Radiology</i> , 2020, 45, 2755-2763.	1.0	11
61	Women in focus: advice from the front lines on how to enable well-being and build resilience. <i>Insights Into Imaging</i> , 2020, 11, 55.	1.6	2
62	Colorectal liver metastases: radiopathological correlation. <i>Insights Into Imaging</i> , 2020, 11, 99.	1.6	18
63	Impact of Liver Diseases on Heart and Lungs. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2071-2075.	2.3	2
64	Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular- ⁹⁰ Y cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 2386-2396.	1.9	32
65	Liver CT perfusion: which is the relevant delay that reduces radiation dose and maintains diagnostic accuracy?. <i>European Radiology</i> , 2019, 29, 6550-6558.	2.3	7
66	Targeted and non-targeted liver biopsies carry the same risk of complication. <i>European Radiology</i> , 2019, 29, 5772-5783.	2.3	12
67	Rare Solid Tumor of the Exocrine Pancreas: A Pictorial Review. <i>Seminars in Ultrasound, CT and MRI</i> , 2019, 40, 483-499.	0.7	2
68	Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. <i>European Radiology</i> , 2019, 29, 3791-3801.	2.3	19
69	Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 934-950.	1.1	46
70	Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. <i>Cancer Imaging</i> , 2019, 19, 75.	1.2	29
71	Endovascular Treatment of Arterial Complications After Liver Transplantation: Long-Term Follow-Up Evaluated on Doppler Ultrasound and Magnetic Resonance Cholangiopancreatography. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 381-388.	0.9	11
72	Portal vein variants associated with right hepatectomy: An analysis of abdominal CT angiography with 3D reconstruction. <i>Clinical Anatomy</i> , 2019, 32, 328-336.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2019, 70, 1123-1132.	1.8	37
74	Gender discrepancy in research activities during radiology residency. <i>Insights Into Imaging</i> , 2019, 10, 125.	1.6	18
75	Hepatocellular carcinoma surveillance: Eastern and Western perspectives. <i>Ultrasonography</i> , 2019, 38, 191-199.	1.0	13
76	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
77	Hepatocellular carcinoma surveillance with ultrasound—cost-effectiveness, high-risk populations, uptake. <i>British Journal of Radiology</i> , 2018, 91, 20170436.	1.0	7
78	Benign and malignant hepatocellular lesions in patients with vascular liver diseases. <i>Abdominal Radiology</i> , 2018, 43, 1968-1977.	1.0	44
79	Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents. <i>European Radiology</i> , 2018, 28, 3020-3031.	2.3	10
80	Uncommon evolutions and complications of common benign liver lesions. <i>Abdominal Radiology</i> , 2018, 43, 2075-2096.	1.0	12
81	Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm. <i>Journal of Hepatology</i> , 2018, 68, 715-723.	1.8	83
82	Macrotrabecular—massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , 2018, 68, 103-112.	3.6	159
83	Diagnosis of Budd—Chiari syndrome. <i>Abdominal Radiology</i> , 2018, 43, 1896-1907.	1.0	35
84	Focal Nodular Hyperplasia After Treatment With Oxaliplatin: A Multiinstitutional Series of Cases Diagnosed at MRI. <i>American Journal of Roentgenology</i> , 2018, 210, 775-779.	1.0	31
85	Polycystic liver disease: Hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences. <i>Hepatology</i> , 2018, 68, 652-662.	3.6	25
86	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. <i>Radiology</i> , 2018, 289, 698-707.	3.6	45
87	Inter-reader agreement of CT features of acute mesenteric ischemia. <i>European Journal of Radiology</i> , 2018, 105, 87-95.	1.2	31
88	Reply to “Oxaliplatin-Induced Liver Changes on Gadoxetate Disodium” Enhanced Liver MRI. <i>American Journal of Roentgenology</i> , 2018, 211, W134-W134.	1.0	0
89	Is magnetic resonance imaging useful for the management of patients with rectal villous adenoma? A study of 45 consecutive patients treated by transanal endoscopic microsurgery. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1695-1701.	1.0	5
90	Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data. <i>European Radiology</i> , 2017, 27, 741-748.	2.3	12

#	ARTICLE	IF	CITATIONS
91	Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e304-e311.	0.7	9
92	Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location. <i>European Journal of Radiology</i> , 2017, 89, 156-162.	1.2	38
93	Letter to the Editor re: Should fat in the radiofrequency ablation zone of hepatocellular adenomas raise suspicion for residual tumour?. <i>European Radiology</i> , 2017, 27, 2235-2236.	2.3	0
94	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
95	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1624-1636.	5.1	595
96	Liver transarterial embolizations in metastatic neuroendocrine tumors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 459-471.	2.6	38
97	Molecular classification of hepatocellular adenoma in clinical practice. <i>Journal of Hepatology</i> , 2017, 67, 1074-1083.	1.8	119
98	A Rare Cause of Pancreatitis. <i>Gastroenterology</i> , 2017, 153, 655-656.	0.6	1
99	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome. <i>Radiology</i> , 2017, 283, 280-292.	3.6	54
100	Risks factors for severe pain after selective liver transarterial chemoembolization. <i>Liver International</i> , 2017, 37, 583-591.	1.9	21
101	Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. <i>European Radiology</i> , 2017, 27, 1748-1759.	2.3	80
102	VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. <i>JMIR Research Protocols</i> , 2017, 6, e17.	0.5	11
103	Functional imaging in liver tumours. <i>Journal of Hepatology</i> , 2016, 65, 1017-1030.	1.8	45
104	Optimal visualization of focal nodular hyperplasia: quantitative and qualitative evaluation of single and multiphase arterial phase acquisition at 1.5T MR imaging. <i>Abdominal Radiology</i> , 2016, 41, 990-1000.	1.0	4
105	Cannabinoid receptor activation in the juvenile rat brain results in rapid biomechanical alterations: Neurovascular mechanism as a putative confounding factor. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 954-964.	2.4	12
106	Safety of supramesocolic surgery in patients with portal cavernoma without portal vein decompression. Large single centre experience. <i>Hpb</i> , 2016, 18, 623-629.	0.1	5
107	Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. <i>Hpb</i> , 2016, 18, 684-690.	0.1	35
108	Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1070-1090.	1.9	19

#	ARTICLE	IF	CITATIONS
109	Imaging of Hepatic Focal Nodular Hyperplasia: Pictorial Review and Diagnostic Strategy. <i>Seminars in Ultrasound, CT and MRI</i> , 2016, 37, 511-524.	0.7	32
110	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 1491-1500.	1.3	31
111	Avoiding Pitfalls in the Interpretation of Gadoteric Acid-Enhanced Magnetic Resonance Imaging. <i>Seminars in Ultrasound, CT and MRI</i> , 2016, 37, 561-572.	0.7	12
112	Development of Collateral Pathways in Tumor Obstruction of Confluence of the Hepatic Veins: Neither Fortuitous nor Innocuous. <i>Journal of the American College of Surgeons</i> , 2016, 223, 595-601.	0.2	4
113	Indication of Percutaneous Microwave Ablation for the Treatment of Hepatic Adenomas: Squaring the Circle. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 932-933.	0.2	2
114	Response: Transient liver modifications associated with abdominal sepsis are various and underestimated. <i>European Radiology</i> , 2016, 26, 4327-4328.	2.3	0
115	Multiparametric magnetic resonance imaging in patients with chronic liver disease: are we there yet?. <i>Liver International</i> , 2016, 36, 631-633.	1.9	0
116	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. <i>European Radiology</i> , 2016, 26, 3094-3101.	2.3	19
117	A meta-analysis of diffusion-weighted and gadoteric acid-enhanced MR imaging for the detection of liver metastases. <i>European Radiology</i> , 2016, 26, 4595-4615.	2.3	126
118	Transient excess of liver fat detected by magnetic resonance imaging in women with acute fatty liver of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 127-129.	0.7	22
119	Endovascular management of delayed post-pancreatectomy haemorrhage. <i>European Radiology</i> , 2016, 26, 3456-3465.	2.3	27
120	Cone-Beam CT Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumors: Comparison of Conventional and Dedicated-Software Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 32-38.	0.2	28
121	Pitfalls in Liver Imaging. <i>Radiology</i> , 2016, 278, 34-51.	3.6	43
122	Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. <i>Journal of Hepatology</i> , 2016, 64, 708-716.	1.8	37
123	Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection. <i>Surgery</i> , 2016, 159, 1050-1057.	1.0	14
124	Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 8-20.	0.9	63
125	Hepatic Proliferation and Angiogenesis Markers Are Increased after Portal Deprivation in Rats: A Study of Molecular, Histological and Radiological Changes. <i>PLoS ONE</i> , 2015, 10, e0125493.	1.1	10
126	Assessment of liver ablation using cone beam computed tomography. <i>World Journal of Gastroenterology</i> , 2015, 21, 517.	1.4	24

#	ARTICLE	IF	CITATIONS
127	Hepatocellular Carcinoma With Osseous Metaplasia and Bone Marrow Elements. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e26-e27.	2.4	2
128	Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. <i>Quality of Life Research</i> , 2015, 24, 2499-2506.	1.5	26
129	Combined Transhepatic Portal Venous and Transarterial Treatment of Superior Mesenteric Arteriovenous Fistula in a Patient with Cirrhosis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 601-603.	0.2	4
130	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2466-2473.	1.9	24
131	Is magnetic resonance imaging of hepatic hemangioma any different in liver fibrosis and cirrhosis compared to normal liver?. <i>European Journal of Radiology</i> , 2015, 84, 816-822.	1.2	15
132	Shear-wave Elastography for the Noninvasive Diagnosis of Focal Liver Lesions: It Always Starts with the Clinical Context. <i>Radiology</i> , 2015, 276, 928-929.	3.6	0
133	Viscoelastic Parameters for Quantifying Liver Fibrosis: Three-Dimensional Multifrequency MR Elastography Study on Thin Liver Rat Slices. <i>PLoS ONE</i> , 2014, 9, e94679.	1.1	20
134	Clinical studies in hepatocellular carcinoma. <i>Future Oncology</i> , 2014, 10, 13-16.	1.1	2
135	Hepatic capsular retraction: spectrum of diagnosis at MRI. <i>Acta Radiologica Short Reports</i> , 2014, 3, 204798161454566.	0.7	4
136	Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 474.	0.7	38
137	Hepatic hemangiomas: Factors associated with T2 shine-through effect on diffusion-weighted MR sequences. <i>European Journal of Radiology</i> , 2014, 83, 468-478.	1.2	36
138	Re: "Radiofrequency Ablation of Hepatic Cysts: Evaluation of Therapeutic Efficacy". <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 808.	0.2	0
139	Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial. <i>European Journal of Cancer</i> , 2014, 50, 3098-3106.	1.3	69
140	The Liver Halo Sign after Tumor Ablation. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1641-1643.	0.2	1
141	Diagnosis and management of solid benign liver lesions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 737-749.	8.2	89
142	Hepatocellular carcinoma: Diagnostic criteria by imaging techniques. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 795-812.	1.0	37
143	Imaging of benign hepatocellular lesions: Current concepts and recent updates. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 681-688.	0.7	48
144	Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification. <i>Hepatology</i> , 2011, 53, 1182-1191.	3.6	180

#	ARTICLE	IF	CITATIONS
145	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. <i>Hepatology</i> , 2011, 54, 1987-1997.	3.6	309
146	A Single-Center Surgical Experience of 122 Patients With Single and Multiple Hepatocellular Adenomas. <i>Gastroenterology</i> , 2009, 137, 1698-1705.	0.6	347
147	Sequential Arterial and Portal Vein Embolization in Patients with Cirrhosis and Hepatocellular Carcinoma: The Hospital Beaujon Experience. <i>Seminars in Interventional Radiology</i> , 2008, 25, 155-161.	0.3	13
148	Focal nodular hyperplasia. <i>European Journal of Radiology</i> , 2006, 58, 236-245.	1.2	132
149	Atrophy-Hypertrophy Complex in Patients with Cavernous Transformation of the Portal Vein: CT Evaluation. <i>Radiology</i> , 2006, 241, 149-155.	3.6	83
150	Tumour detection in the liver: role of multidetector-row CT. <i>European Radiology, Supplement</i> , 2005, 15, d85-d88.	1.8	2
151	Prevalence of Hepatic Hemangioma in Patients with Focal Nodular Hyperplasia: MR Imaging Analysis. <i>Radiology</i> , 2003, 229, 75-79.	3.6	123
152	Peritoneal carcinomatosis in patients with digestive endocrine tumors. <i>Cancer</i> , 1996, 78, 1686-1692.	2.0	54
153	Correlation of MR changes with doppler US measurements of blood flow in exercising normal muscle. <i>Journal of Magnetic Resonance Imaging</i> , 1992, 2, 645-652.	1.9	11
154	Comparison between ultrasonographic signs and the degree of portal hypertension in patients with cirrhosis. <i>Gastrointestinal Radiology</i> , 1990, 15, 218-222.	0.4	81